tbuckley/cabot-search huggingface dataset:
THU0200 Sustained and Similar Clinical Response to Etanercept After 6 Years of Treatment in Patients with Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Long-term Results of the Esther Trial
Authors: D. Poddubnyy, I.-H. Song, K.-G. Hermann, H. Haibel, J. Callhoff, J. Listing, B. Buss, B. Freundlich, E. Lange, M. Rudwaleit, J. Sieper
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To assess the long-term clinical efficacy of etanercept (ETN) in patients with early axial spondyloarthritis (including both non-radiographic axial SpA – nr-axSpA and radiographic axial SpA – ankylosing spondylitis, AS) with a symptom duration of &lt;5 years who participated in the long-tem (until year 6) extension of the ESTHER trial [1]. <h3>Methods</h3> In the previously reported core phase ESTHER trial axial SpA patients were treated with ETN (n=40) versus sulfasalazine (n=36) during 48 weeks [1]. After one year all patients were treated continuously with ETN (a few (n=12) patients temporarily interrupted treatment in the 2nd year to assess time to flare and were then (re-)treated with ETN) [2]. Clinical efficacy data were analysed for patients who completed six years of treatment. <h3>Results</h3> Out of 76 patients who entered the study at baseline, 44.7% (n=34, 17 with nr-axSpA and 17 with AS) completed year 6 of the study. In both subgroups a constantly and similarly good clinical response was observed until year 6 with more than a half of the patients in both groups reaching an ASAS partial remission response at year 6 (table). Similarly high and comparable between groups were ASAS40 response and a 50% improvement of BASDAI as compared to baseline. Mean BASDAI and BASFI values were constantly &lt;2 at years 4, 5 and 6 in both groups (table). <h3>Conclusions</h3> There was a sustained and similar clinical response in patients with nr-axSpA and AS treated with ETN over 6 years. Similar clinical response indicates that the presence or absence of radiographic sacroiliitis at baseline does not determine clinical response to anti tumour necrosis factor therapy over time that supports the concept of axial SpA as one disease. <h3>References</h3> Song IH, et al. Ann Rheum Dis 2011;70:590-6. Song IH, et al. Ann Rheum Dis 2012;71:1212-5. <h3>Acknowledgements</h3> The study was supported by an unrestricted research grant von Pfizer. <h3>Disclosure of Interest</h3> D. Poddubnyy Consultant for: Abbvie, MSD, Pfizer, UCB, I.-H. Song Employee of: Abbvie, K.-G. Hermann Speakers bureau: Abbvie, MSD, Pfizer, UCB, H. Haibel: None declared, J. Callhoff: None declared, J. Listing: None declared, B. Buss: None declared, B. Freundlich: None declared, E. Lange Employee of: Pfizer, M. Rudwaleit Consultant for: Abbvie, MSD, Pfizer, UCB, J. Sieper Grant/research support from: Abbvie, MSD, Pfizer, Consultant for: Abbvie, MSD, Pfizer, UCB
The Water Jet-guided Nd:YAG Laser in the Treatment of Gastroduodenal Ulcer with a Visible Vessel
Authors: R Sander, H Poesl, W Zuern, A Spuhler, M Braida
Journal: Endoscopy (1989)

In a randomized, prospective study, 57 patients with a gastroduodenal ulcer and a visible vessel with or without spurting bleeding were treated with a Nd:YAG laser (lambda = 1.064 nm). Twenty-eight of these patients were treated using the conventional non-contact (NC) modality, and 29 were treated with the water jet (WJ) laser. Apart from the technical advantages (minimal smoke development, no damage to adjacent structures) the WJ group had a lower rate of induced spurting bleeds (25% WJ versus 55% NC). The therapeutic failure/mortality rate of 7%/0% respectively for the water-jet group was lower than the 18%/7% for the non-contact group. The initial clinical results of this study suggest that the water-jet Nd:YAG laser system is superior to the non-contact system.
PTU-187 Sample size calculation in confirmatory trials in irritable bowel syndrome with constipation: experience with linaclotide (constella®): Abstract PTU-187 Table 1
Authors: M Falques, C Díaz, D Vilardell, J Fortea, JM Johnston
Journal: Gut (2015)

<h3>Introduction</h3> Sample size (SS) calculation with sufficient power to detect significant and clinically meaningful differences vs placebo is necessary to ensure the validity of confirmatory Phase 3 pivotal trials in irritable bowel syndrome with constipation (IBS-C). <h3>Method</h3> Using data from a pilot Phase 2b study of linaclotide (Constella<sup>®</sup>; LIN) in IBS-C (Study 202) and the pivotal Phase 3 LIN trials (Trial 302; Trial 31), we compared 2 statistical assumptions for the Phase 3 SS calculation for the European Medicines Agency (EMA) co-primary endpoints: 1) minimally important clinical differences (MICD) and 2) replication of Phase 2b 290 µg/day results. Protocol design, patient population and endpoints of the trials were also compared. <h3>Results</h3> There were no relevant differences in protocol design or patient population in the Phase 2b/3 trials. For endpoint assessments, only the range of the pain/discomfort scale differed (Phase 2b: range 1–5; Phase 3: range 0–10). For both EMA endpoints, Phase 2b data showed a higher placebo effect and greater improvement vs placebo compared with Phase 3 data (both not statistically significant; Table 1). The SS for the Phase 3 trials was estimated to have ≥95% global power to detect an MICD of 15% in both endpoints. Based on replication of Phase 2b results, an SS of 134 patients per treatment arm would have been sufficient to achieve ≥95% global power to detect an effect size comparable to Phase 2b. However, this sample size would have only 46% and 67% overall power to detect the actual observed results of Trials 31 and 302, respectively, and even less overall power (13% and 47%, respectively) when the MICD is reduced to 10%. <h3>Conclusion</h3> In the LIN IBS-C clinical programme, Phase 2b results were not a good predictor of Phase 3 outcome, even without major differences in study design. Caution is needed when calculating SS for Phase 3 IBS-C trials to ensure sufficient power to detect clinically relevant differences vs placebo. <h3>Disclosure of interest</h3> M. Falques Employee of: Almirall S. A., C. Díaz Employee of: Almirall S. A., D. Vilardell Employee of: Almirall S. A., J. Fortea Employee of: Almirall S. A., J. Johnston Employee of: Ironwood Pharmaceuticals.
Developmental perspectives in child and adolescent depressive symptoms in a community sample
Authors: J H Kashani, T K Rosenberg, J C Reid
Journal: American Journal of Psychiatry (1989)

This developmental study provides some normative data on the distribution of depressive symptoms in 210 children and adolescents in three different age groups (8, 12, and 17 years) from a nonclinically referred sample. The Child Assessment Schedule and other instruments were used. Studying depression from a dimensional point of view, the authors found withdrawal, pessimism, horrible dreams, and suicidal ideation and tendency in the different age groups to be closely related to depressive symptoms.
von Willebrand Factor Propeptide in Vascular Disorders: A Tool to Distinguish Between Acute and Chronic Endothelial Cell Perturbation
Authors: Jan A. van Mourik, Ria Boertjes, Inge A. Huisveld, Karin Fijnvandraat, Dasja Pajkrt, Perry J.J. van Genderen, Rob Fijnheer
Journal: Blood (1999)
Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine
Authors: D L Garver, H Dekirmenjian, J M Davis, R Casper, S Ericksen
Journal: American Journal of Psychiatry (1977)

The authors studied neuroleptic concentration-therapeutic response curves for butaperazine (BPZ), a piperazine phenothiazine, in 10 schizophrenic patients during the first 12 days of treatment. BPZ bound to red blood cells (RBC) was more strongly correlated with therapeutic response than was plasma BPZ. RBC BPZ concentrations could be used to define a "therapeutic window", an optimun concentration for therapeutic response, above and below which favorable response diminishes. The authors emphasize the preliminary nature of the data but suggest that levels of RBC-bound neuroleptic may provide an important guide for dosage regulation in schizophrenic patients.
THU0136 Concordance Between Joint Symptom/Tenderness/Swelling and Ultrasonography (US) Synovitis in Rheumatoid Arthritis: Which Clinical Finding is More or Less Relevant to us Synovitis than Others?: Table 1.
Authors: A. Hirata, T. Ogura, N. Hayashi, Y. Fujisawa, S. Nakahashi, K. Mizushina, M. Imamura, S. Takenaka, H. Ito, H. Kameda
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Recently ultrasonography (US) has been prevalent as a valid and objective modality of joint examination in patients with rheumatoid arthritis (RA). However, few studies have reported the agreement between subjective joint symptoms and US synovitis at each joint level. <h3>Objectives</h3> The aim of this study was to examine and compare the concordance between joint symptom/tenderness/swelling and US synovitis. <h3>Methods</h3> Fifty patients with RA (84% female, the median age, disease duration and disease activity score of 28 joints (DAS28) were 69 years, 2.4 years, and 3.8, respectively) were asked for the self-evaluation of joint symptoms including pain and considerable stiffness in (proximal) interphalangeal (IP/PIP), metacarpophalangeal (MCP), wrist, elbow, shoulder, knee and ankle joints. Those joints were evaluated by physical examination for the presence of tenderness and/or swelling, and also by US for the presence of synovitis defined as gray-scale score ≥2 or power Doppler signal score ≥1. <h3>Results</h3> In a total of 1494 evaluated joints, joint symptoms, tenderness and swelling were observed in 288 joints (19.3%), 182 joints (12.2%), and 220 joints (14.7%), respectively, and US synovitis was observed in 317 joints (21.2%).The overall concordance rate with US synovitis was the least for joint tenderness (κ=0.30) when compared with joint symptoms (κ=0.39) or swelling (κ=0.43), irrespective of the evaluated joint except for the elbow (Table 1). Moreover, the percentage of inflamed joint clinically detected only by joint symptom, tenderness, or swelling was 4.0%, 0.5% and 1.8%, respectively, when US synovitis was defined as a gold standard. <h3>Conclusions</h3> Joint examination for the presence of swelling is crucial, and that for the presence of tenderness can be excluded from clinical joint assessment, or it may be better substituted by patient-reported joint symptoms. A recent proposal of the modification of composite activity measures such as simplified disease activity index (SDAI) by removing tender joint count (and patient9s global assessment) in order to improve the correlation with magnetic resonance imaging (MRI) synovitis may, at least in part, support our results. <h3>References</h3> Backer J, et al. Arthritis Rheum 2014;66:794-802 <h3>Disclosure of Interest</h3> None declared
Allergic Reactions to Tetanus, Diphtheria, Influenza and Poliomyelitis Immunization
Authors: R E SMITH, C WOLNISTY
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Colleagues' responses to the pregnant psychiatric resident
Authors: N T Butts, J O Cavenar
Journal: American Journal of Psychiatry (1979)

A number of researchers have suggested that the pregnant psychiatrist has many intrapsychic conflicts, as a result of the pregnancy, which influence her interactions with colleagues. In contrast, the authors suggest that colleagues' reactions to the pregnancy may be based on their intrapsychic conflicts, which create internal conflicts for the pregnant psychiatrist and affect her relationships with her colleagues. The authors present case reports involving psychiatric residents that illustrate their thesis.
Continuing certification and continuing education
Authors: C B Robinowitz, M Greenblatt
Journal: American Journal of Psychiatry (1980)

The authors review the guidelines of the American Board of Medical Specialties (ABMS) for recertification and the approaches of various medical specialty boards, including internal medicine, pathology, and family practice, toward implementing periodic recertification. At a time when psychiatry has an increasingly close alliance with the other medical specialties, it is important that this issue receive serious consideration. Close collaboration between APA and the ABPN on the recertification process assures that any procedures developed will be in keeping with psychiatrists' wishes and needs, while meeting the responsibility for public accountability.
Mental illness in the biological and adoptive relatives of schizophrenic adoptees: findings relevant to genetic and environmental factors in etiology
Authors: S S Kety
Journal: American Journal of Psychiatry (1983)

Previous studies by the author and his collaborators, Rosenthal, Wender, Schulsinger, and Jacobsen, of the biological and adoptive relatives of schizophrenic adoptees are reviewed in conjunction with more recent studies by Spitzer and Endicott and by Kendler, Gruenberg, and Strauss, who independently made operational diagnoses using the Research Diagnostic Criteria or DSM-III specifications, both of which showed good agreement with the authors' global diagnoses based on the descriptions in DSM-II. Both the DSM-III diagnoses and the authors' global diagnoses found a highly significant concentration of chronic, latent, and uncertain schizophrenia or schizotypal personality disorder in the biological relatives of adoptees who developed chronic schizophrenia. A response is made to recent criticisms published in this journal by Lidz and Blatt and by Abrams and Taylor.
Antecedents and consequences of negative life events in adulthood: a longitudinal study
Authors: X J Cui, G E Vaillant
Journal: American Journal of Psychiatry (1996)

This study investigated whether negative life events affected subjects' long-term physical and mental health.One hundred thirteen normal college men completed biennial follow-up questionnaires from age 26 until age 62. At age 62 they retrospectively assessed 16 major negative life events with a self-report checklist. A blind rater read each man's complete records over the 35 years and completed the same checklist prospectively. The men had independent physical examinations at age 65.It was demonstrated that negative life events affect men's psychological health more than their physical health. The correlation of negative life events with physical health was so low that no significant relationship between the two variables could be established. Negative life events were significantly associated with affective spectrum disorder and its relevant indicators. Further, the Cox proportional hazards model revealed that negative life events, family history of depression, and psychosocial stability during the college years were independent and statistically significant predictors of depression.This study supports the widely held belief that biological factors (heredity), psychological factors (unstable personality), and social factors (negative life events) are all etiologically related to depression.
Improving services with informatics tools
Authors: Frank Sullivan, Jeremy C Wyatt
Journal: BMJ (2005)

This article describes how many sources of data can be linked, interpreted, and analysed before being presented to decision makers to improve care.It also discusses the legal issues surrounding data protection and freedom of information.A huge volume of data flows across the desk of a director of public health (see box opposite).One of the director's problems is to know which signals to act upon and what "noise" to ignore.If the numbers being considered are small, as they probably will be in the case described here, a critical incident analysis may be all that is needed.An individual prescriber, or group, may have an erroneous belief or inadequate training.Critical incidents or other signals often indicate that more data (such as data on prescribing steroids for paediatric asthma in primary care and outpatients) are needed. Sources of dataHealth services are awash with data.Earlier articles in the series described the large and increasing numbers of sources of data available to consumers, patients, clinicians, and administrators.Clinicians, teams, divisions, and other groups collect the data they need to carry out their work, and they may do so using coding and terms that others can understand and share.The intensive care unit in this example integrated the data the team needs to manage patients during their stay with patients' pre-admission prescribing data.This local epidemiology may have been done as part of clinical governance activities, or as an ad hoc exercise when a patient's problem was investigated.One difficulty with secondary uses of clinical data is that, having obtained the data indicating a problem exists, the issue must be dealt with effectively.It may be that the individual or group who identify the problem have the knowledge, skills, and resources to resolve it.In other cases, such as these potentially avoidable asthma admissions, those responsible are not those who have uncovered the issue, and those potentially responsible may be unaware of the problem.
OP0019 Osteoarthritis, Drug Use and Risk of Cardiac Ischaemic Events: A Case-Control Study
Authors: C. Pontes, R. Morros, J.R. Marsal, F. de Abajo, J.R. Castillo, J. Rios, X. Carné, P. Du Souich
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Recent controversies on the safety profile of drugs used to treat osteoarthritis (OA) have led to changes in clinical guidance for management (1). <h3>Objectives</h3> To describe associations between the use of different OA drug therapies and the risk of cardiac ischemic events (CIE). <h3>Methods</h3> We conducted a nested case-control study within a cohort of patients with clinically diagnosed OA (according to ICD10 codes in the SIDIAP database of primary care records for over 5 million people in Catalonia, Spain (2)). Cases were identified in the period between 2008 and 2012 through ICD10 codes of cardiac ischemic events (CIE) (AIM or unstable angina, fatal or not) and cross-checked with hospital discharge diagnosis; 3 controls without CIE were matched to each case by sex, age (±5 years), area and year (±2 years) of first diagnosis of OA. Data were linked with pharmacy invoicing information, encrypted and extracted for analysis. Exposure to NSAIDs, SYSADOAs, opioids, paracetamol and metamizole were analysed. Adjusted multivariate conditional logistic regression models were fitted to estimate odds ratio (OR) for CIE according to drug use. <h3>Results</h3> We studied 5663 cases and 16989 matched controls. Cases had more morbidity and cardiovascular risk factors, but similar characteristics for OA and joint involvement. Significantly increased risks (OR 95%CI) were observed related to the use of non-selective NSAIDs (1.10 (95%CI 1.01 to 1.19)), in particular for diclofenac (1.16 (1.07 to 1.25)) and naproxen (1.14 (1.01 to 1.29)), and for opioid analgesics (1.13 (1.04 to 1.24)). SYSADOAS, paracetamol and metamizole showed no significant associations with CIE. <h3>Conclusions</h3> In patients with OA, non-selective NSAIDs (diclofenac, naproxen) and opioid analgesics are associated to an increased risck of CV events. This should be considered for the management of OA patients with a high cardiovascular risk profile. <h3>References</h3> National Institute for Health Care and Excellence. Osteoarthritis care and management in adults. National Institute for Health and Care Excellence (United Kingdom), 2014. www://www.nice.org.uk/guidance/cg177/resources/guidance-osteoarthritis-pdf (accessed 25th January 2015). Bolíbar B, Fina F, Morros R et al. SIDIAP database: electronic clinical records in Primary Care as a source of information for epidemiologic research. Med Clin (Barc) 2012;138(14):617-21. <h3>Acknowledgements</h3> The study was funded by Bioibérica S.A. <h3>Disclosure of Interest</h3> None declared
Out of Africa
Authors: Demetrios J. Sahlas, J. Dick MacLean, John Janevski, Allan S. Detsky
Journal: New England Journal of Medicine (2002)

A 42-year-old man who had been a human-rights leader in the Democratic Republic of Congo presented with emotional distress and difficulty coping. He had been tortured while imprisoned during the recent civil war and was having personal and financial difficulties. A mental-status examination revealed delusional thinking. Physical examination was normal, and routine laboratory testing was remarkable only for a normochromic, normocytic anemia.
Senescence Can Be BETter without the SASP?
Authors: Maria Grazia Vizioli, Peter D. Adams
Journal: Cancer Discovery (2016)

Abstract Summary: Global remodeling of the chromatin landscape occurs during senescence, although its functional consequence is still unclear. In this issue, Tasdemir and colleagues show that the epigenetic regulator BRD4 is required for expression of the proinflammatory senescence-associated secretory phenotype and immune clearance of senescent cells in vitro and in vivo. Their results could be useful in the design of novel therapies to treat aging-related diseases, including cancer.Cancer Discov; 6(6); 576–8. ©2016 AACR. See related article by Tasdemir et al., p. 612.